Switch to:
Also traded in: Austria, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.73
NAS:ILMN's Cash-to-Debt is ranked lower than
51% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. NAS:ILMN: 1.73 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ILMN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 1.65 Max: 16544
Current: 1.73
0.69
16544
Equity-to-Asset 0.57
NAS:ILMN's Equity-to-Asset is ranked lower than
57% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NAS:ILMN: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ILMN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.56 Max: 0.94
Current: 0.57
0.36
0.94
Debt-to-Equity 0.41
NAS:ILMN's Debt-to-Equity is ranked lower than
59% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. NAS:ILMN: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ILMN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.48 Max: 1.5
Current: 0.41
0
1.5
Debt-to-EBITDA 1.04
NAS:ILMN's Debt-to-EBITDA is ranked higher than
65% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. NAS:ILMN: 1.04 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ILMN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.49  Med: 1.93 Max: 3.42
Current: 1.04
-1.49
3.42
Interest Coverage 15.18
NAS:ILMN's Interest Coverage is ranked lower than
66% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.21 vs. NAS:ILMN: 15.18 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ILMN' s Interest Coverage Range Over the Past 10 Years
Min: 3.38  Med: 5.73 Max: 17.69
Current: 15.18
3.38
17.69
Piotroski F-Score: 6
Altman Z-Score: 10.63
Beneish M-Score: -2.84
WACC vs ROIC
6.62%
22.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 20.01
NAS:ILMN's Operating Margin % is ranked higher than
86% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. NAS:ILMN: 20.01 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ILMN' s Operating Margin % Range Over the Past 10 Years
Min: -82.12  Med: 18.88 Max: 27.65
Current: 20.01
-82.12
27.65
Net Margin % 30.14
NAS:ILMN's Net Margin % is ranked higher than
95% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. NAS:ILMN: 30.14 )
Ranked among companies with meaningful Net Margin % only.
NAS:ILMN' s Net Margin % Range Over the Past 10 Years
Min: -75.89  Med: 12.01 Max: 30.14
Current: 30.14
-75.89
30.14
ROE % 30.86
NAS:ILMN's ROE % is ranked higher than
93% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. NAS:ILMN: 30.86 )
Ranked among companies with meaningful ROE % only.
NAS:ILMN' s ROE % Range Over the Past 10 Years
Min: -84.48  Med: 10.45 Max: 30.86
Current: 30.86
-84.48
30.86
ROA % 16.98
NAS:ILMN's ROA % is ranked higher than
92% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. NAS:ILMN: 16.98 )
Ranked among companies with meaningful ROA % only.
NAS:ILMN' s ROA % Range Over the Past 10 Years
Min: -43.21  Med: 5.8 Max: 16.98
Current: 16.98
-43.21
16.98
ROC (Joel Greenblatt) % 119.16
NAS:ILMN's ROC (Joel Greenblatt) % is ranked higher than
97% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. NAS:ILMN: 119.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ILMN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -508.83  Med: 75.57 Max: 136.47
Current: 119.16
-508.83
136.47
3-Year Revenue Growth Rate 16.80
NAS:ILMN's 3-Year Revenue Growth Rate is ranked higher than
86% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. NAS:ILMN: 16.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ILMN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1  Med: 22.9 Max: 156.2
Current: 16.8
-1
156.2
3-Year EBITDA Growth Rate 32.80
NAS:ILMN's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. NAS:ILMN: 32.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ILMN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -73.6  Med: 24.15 Max: 608.3
Current: 32.8
-73.6
608.3
3-Year EPS without NRI Growth Rate 50.50
NAS:ILMN's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. NAS:ILMN: 50.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ILMN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.1  Med: 18.15 Max: 211.5
Current: 50.5
-41.1
211.5
GuruFocus has detected 3 Warning Signs with Illumina Inc NAS:ILMN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ILMN's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ILMN Guru Trades in Q4 2016

Joel Greenblatt 3,565 sh (New)
Andreas Halvorsen 349,965 sh (New)
Steven Cohen 25,500 sh (New)
Vanguard Health Care Fund 3,162,479 sh (+4.35%)
First Eagle Investment 400 sh (unchged)
Jana Partners 405,400 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 2,079,730 sh (-0.17%)
Frank Sands 5,713,188 sh (-8.49%)
Ron Baron 456,447 sh (-53.62%)
Eaton Vance Worldwide Health Sciences Fund 89,595 sh (-50.23%)
» More
Q1 2017

ILMN Guru Trades in Q1 2017

George Soros 1,402 sh (New)
Paul Tudor Jones 1,693 sh (New)
Ray Dalio 39,843 sh (New)
Ron Baron 458,490 sh (+0.45%)
First Eagle Investment 400 sh (unchged)
Joel Greenblatt Sold Out
Andreas Halvorsen Sold Out
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 2,072,110 sh (-0.37%)
Frank Sands 5,495,268 sh (-3.81%)
Vanguard Health Care Fund 2,948,379 sh (-6.77%)
» More
Q2 2017

ILMN Guru Trades in Q2 2017

Jim Simons 270,918 sh (New)
Caxton Associates 1,800 sh (New)
Steven Cohen 63,500 sh (New)
Spiros Segalas 1,923,199 sh (+57.82%)
First Eagle Investment 400 sh (unchged)
Paul Tudor Jones Sold Out
George Soros Sold Out
PRIMECAP Management 2,035,420 sh (-1.77%)
Ron Baron 448,557 sh (-2.17%)
Frank Sands 5,218,222 sh (-5.04%)
Vanguard Health Care Fund 2,666,434 sh (-9.56%)
Ray Dalio 18,723 sh (-53.01%)
» More
Q3 2017

ILMN Guru Trades in Q3 2017

Ray Dalio 63,012 sh (+236.55%)
First Eagle Investment 400 sh (unchged)
Caxton Associates Sold Out
Ron Baron 444,335 sh (-0.94%)
Steven Cohen 62,800 sh (-1.10%)
Frank Sands 4,926,817 sh (-5.58%)
PRIMECAP Management 1,903,230 sh (-6.49%)
Vanguard Health Care Fund 1,920,681 sh (-27.97%)
Jim Simons 133,218 sh (-50.83%)
Spiros Segalas 1,523,457 sh (-20.79%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -27.97%0.28%$169 - $213.93 $ 209.029%1,920,681
Ron Baron 2017-09-30 Reduce -0.94%$169 - $213.93 $ 209.029%444,335
Vanguard Health Care Fund 2017-06-30 Reduce -9.56%0.11%$167.48 - $188.85 $ 209.0218%2,666,434
Ron Baron 2017-06-30 Reduce -2.17%0.01%$167.48 - $188.85 $ 209.0218%448,557
George Soros 2017-06-30 Sold Out 0.01%$167.48 - $188.85 $ 209.0218%0
Vanguard Health Care Fund 2017-03-31 Reduce -6.77%0.07%$131.13 - $173.16 $ 209.0229%2,948,379
Ron Baron 2017-03-31 Add 0.45%$131.13 - $173.16 $ 209.0229%458,490
George Soros 2017-03-31 New Buy0.01%$131.13 - $173.16 $ 209.0229%1,402
Joel Greenblatt 2017-03-31 Sold Out 0.01%$131.13 - $173.16 $ 209.0229%0
Vanguard Health Care Fund 2016-12-31 Add 4.35%0.04%$122.02 - $186.17 $ 209.0251%3,162,479
Ron Baron 2016-12-31 Reduce -53.62%0.51%$122.02 - $186.17 $ 209.0251%456,447
Joel Greenblatt 2016-12-31 New Buy0.01%$122.02 - $186.17 $ 209.0251%3,565
George Soros 2016-12-31 Sold Out 0.02%$122.02 - $186.17 $ 209.0251%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334516    SIC: 3826
Compare:XPAR:EI, NYSE:BAX, NYSE:BCR, OCSE:COLO B, NYSE:MTD, NYSE:WAT, TSE:4543, NAS:XRAY, NYSE:BDX, TSE:7733, NYSE:RMD, NYSE:COO, XSWX:STMN, NAS:HOLX, NYSE:STE, NYSE:WST, OSTO:GETI B, SZSE:002294, NYSE:HRC, NYSE:CMD » details
Traded in other countries:ILMN.Austria, ILU.Germany, ILMN.Mexico,
Headquarter Location:USA
Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

Illumina is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, and MiniSeq product lines.

Guru Investment Theses on Illumina Inc

Baron Opportunity Fund Comments on Illumina - Feb 21, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell in the fourth quarter after reporting disappointing third quarter financial results. The third quarter shortfall was driven by weak high-throughput instrument sales. However, at the J.P. Morgan Healthcare Conference in January, Illumina announced an exciting new high-throughput sequencing platform, called NovaSeq, which has the potential in future years to deliver the world’s first $100 full human genome. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. (Neal Kaufman)



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Illumina - Feb 13, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell almost 30% after reporting disappointing third quarter financial results. The shortfall was caused primarily by weak high-throughput instrument sales in North America and general weakness in Europe. Illumina’s growth is very much driven by new product introductions, and in 2016 sales suffered as the high- throughput instrument line reached the end of its life cycle. In early 2017, Illumina launched a new high- throughput sequencing platform that should re-accelerate growth. In addition, Grail, the start-up funded by Illumina which is developing a blood-based cancer screening test, announced it received capital commitments of $1 billion and would become one of Illumina’s largest customers over time. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Asset Fund Comments on Illumina Inc. - Jan 30, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell after reporting disappointing financial results. The quarterly shortfall was driven by weak sales of its high-throughput instruments. We reduced the size of our position but continue to own the stock because we believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. We are encouraged that the shares have had a meaningful recovery in early January, as the company provided encouraging earnings guidance for 2017 and launched a powerful, new DNA sequencing platform.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Oct 25, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, contributed to performance in the third quarter. The company reported financial results that beat Wall Street expectations and reiterated guidance for the year. Unfortunately, after quarter end, Illumina pre-announced weaker-than-expected third quarter results and guided down its fourth quarter, and its stock has retreated. While we acknowledge that Illumina may be in a soft patch until we hit an inflection point in the adoption of genetic sequencing for actual patient care, with oncology being the largest opportunity, we continue to believe Illumina has strong moats around its DNA sequencing platform and a long runway for growth. (Neal Kaufman)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - Oct 21, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, gained after the company reported financial results that exceeded Wall Street’s expectations. The results confirmed strong demand both for the company’s sequencing instruments in the Americas and China, as well as for its products in clinical applications, such as oncology screening and diagnosis. Management also demonstrated its ability to rein in expenses, which helped lead to accelerating EPS growth. We continue to believe Illumina has a long runway for growth, driven by increasing adoption of DNA sequencing technologies, particularly in clinical markets.



From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Jul 13, 2016

Illumina, Inc. (NASDAQ:ILMN) is a health care company that is the leader in platforms used for DNA sequencing, the process of determining the precise order of nucleotides with a DNA molecule. Illumina provides the tools used for over 90% of the world’s sequencing output. Illumina is benefiting from a major shift into personalized medicine driven by DNA sequencing. It is already becoming common practice to sequence a cancerous tumor and prescribe drugs targeting the genetic mutations specific to that cancer. In the reproductive health arena, DNA sequencing is being used to help identify chromosomal abnormalities early in a pregnancy.



When we bought Illumina in 2011, the stock had been decimated by two missed quarters, reduced guidance, and the threat of a government shutdown (at the time, roughly one-third of revenue was from academic research, which relies on federal funding). None of this had to do with Illumina’s competitive advantages or potential growth opportunities. We took advantage of the selloff to establish a position. The stock has appreciated more than 300% in the time we have owned it.



From Baron Funds' Summer 2016 Newsletter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 23, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN) detracted from performance in the first quarter. Illumina is the leading provider of DNA sequencing technology to academic and commercial laboratories. Although fourth quarter financial results were solid, management tempered expectations for the first quarter HiSeq X and benchtop instrument sales. We continue to believe Illumina has a long runway for growth, driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - May 06, 2016

Shares of Illumina, Inc. detracted from performance in the first quarter. Illumina is the leading provider of DNA sequencing technology to academic and commercial laboratories. Although fourth quarter financial results were solid, management tempered expectations for first quarter HiSeq X and benchtop instrument sales. We continue to believe Illumina has a long runway for growth, driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. (Neal Kaufman)





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Apr 26, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell during the quarter. Although Illumina reported solid fourth quarter financial results, management tempered the market’s expectations for sales of its HiSeq X and benchtop instruments during early-2016, and shares reacted negatively. We continue to believe that Illumina has a long runway for growth, driven by the increased adoption of DNA sequencing in large clinical markets, such as those for cancer screening, diagnosis, and treatment.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

A Great Resource for Disruptive Innovations An introduction to ARK Investment
In May of last year, I wrote an article titled "Adapt or Fail: Watch Out for Disruptive Technologies." At the end of the article, I came to the following conclusion: Read more...
Vanguard Health Care Fund Trims Positions in Vertex, Regeneron, Illumina Fund's largest 3rd-quarter sales
Founded in 1984, the Vanguard Health Care Fund (Trades, Portfolio) is managed by Jean Hynes. During the third quarter, the fund reduced its positions in the following stocks: Read more...
Analysis: Positioning to Benefit within Becton, Dickinson and Company, FedEx, Ulta Beauty, Alliance Data Systems, Illumina, and Arista Networks – Research Highlights Growth, Revenue, and Consolidated Results
Azumio Introduces DNA-Based Insights into its Fitness Platform
Apple Fuels Dow Jones Above the 22,000 Mark Market encouraged by 2nd-quarter earnings reports
U.S. stock market indexes opened higher on the Wednesday. Futures for the Dow Jones Industrial Average rose 41 points to 22,004.36, hitting a new high as investors remained optimistic about second-quarter earnings. Also, the Standard & Poor’s 500 index futures fell one point to 2,475.14 and futures for the Nasdaq 100 index jumped 8.63 points to 6,371.57. Read more...
Kindara Unveils Plan To Revolutionize Women's Health Industry With Kindara DNA
Coalition for Access to Prenatal Screening Announces Clinical Advisory Board
OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™

Non-invasive prenatal test that harnesses the power of massively parallel sequencing to screen for fetal chromosomal abnormalities

MIAMI, March 07, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that GenPath Women’s Health, a business unit of OPKO Health subsidiary BioReference Laboratories, will offer ClariTest™, a non-invasive prenatal test (NIPT) initially to be performed at Illumina, Inc. (NASDAQ:ILMN) on the Verifi™ platform.  This platform utilizes massively parallel sequencing technology to screen for trisomies 13, 18, 21 and sex chromosome abnormalities, with the option to screen for 5 microdeletions including 22q11.2 (DiGeorge syndrome).  ClariTest™ can be performed as early as 10 weeks of gestational age, can be performed in twin and egg donor pregnancies, has excellent sensitivity and specificity, and has the lowest failure rate in the industry.
Illumina’s most recent clinical evidence study of Verifi™ was comprised of more than 85,000 clinical samples and demonstrated observed sensitivity and specificity of trisomy 21 at greater than 99%.  Trisomy 18 and trisomy 13 had observed sensitivity at greater than 97% and specificity at greater than 99%. With the industry’s lowest failure rate at 0.1%, Illumina’s Verifi™ service can reduce maternal anxiety by requiring fewer redraws and reliably providing fetal genetic information to a greater number of patients and providers. GenPath Women’s Health will ultimately develop and validate its own laboratory-developed test for NIPT using Illumina’s sequencing technology. Adoption of Illumina’s Verifi™ test allows GenPath to continue to serve the NIPT market using the immense power of whole genome sequencing while developing its own NIPT offering. “We believe the best way to improve patient care is to unlock the power of whole genome sequencing. We are pleased to partner with BioReference and GenPath Women’s Health to expand the use of Illumina technology for women’s health.  The partnership further extends Illumina’s strategy to enable a broader number of customers to offer NIPT on our sequencing technology,” said Jeff Hawkins, Vice President and General Manager of Reproductive Genetic Health at Illumina. “NIPT testing has become an incredibly valuable addition to prenatal care and we are pleased to offer what we believe to be the most technically advanced NIPT test available on the market.  ClariTest is a safe option to help pregnant women and their physicians screen patients who are at an increased risk of a fetal chromosome abnormality,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories. “Patient care is foremost at BioReference and ClariTest provides highly accurate results at an early gestational age.  ClariTest is based on the latest advances in technology, offering superior detection rates compared to conventional screening methods for fetal chromosome abnormalities and can significantly reduce the need for invasive testing, which is associated with an increased risk for adverse pregnancy outcomes, including pregnancy loss.” ClariTest is available from GenPath Women’s Health. As a convenience to patients and physicians alike, the laboratory provides easy-to-read results reports available within 5-7 days after testing, access to an industry-leading team of genetic counselors, contracts with most national insurance carriers, direct-to-patient pricing as part of the Community Health Advocacy Program, the ability to interface with most EMR/EHRs, a comprehensive network of patient service centers and other ancillary support services. About OPKO Health, Inc.: 
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once- or twice-weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists (phase 2), and TT701, an androgen receptor modulator for androgen deficiency indications (phase 2).  Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer) and a long-acting Factor VIIa drug for hemophilia (in phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com. About GenPath Women’s Health:
GenPath Women’s Health and its parent company BioReference Laboratories Inc. are members of the OPKO Health, Inc. (NASDAQ:OPK) group of companies. GenPath Women’s Health is a full-service laboratory offering a complete menu of tests for the OB-GYN and women’s health providers. Since its inception in 2005, GenPath Women’s Health has risen to become one of the premier specialty labs in the country, including the development of an innovative technology platform for sexually transmitted and other vaginal infections, pan-ethnic carrier testing and maternal risk assessment and prenatal diagnosis. GenPath has grown and evolved to become the One Lab for every phase of a patient’s life, offering solutions to all women’s health testing and service needs. In 2015, GenPath launched an industry-leading line of hereditary cancer testing. More information is available at http://www.genpathdiagnostics.com/womens-health/.   This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected benefits of the ClariTest and the performance of the test, whether it will reliably provide fetal genetic information, whether it offers superior detection rates and will significantly reduce the need for invasive testing,  as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. Contacts: OPKO Health, Inc.
David Malina, 305-575-4137 GenPath Women’s Health
Kesha Walker, 201-791-2600 x8651 Media
Rooney Partners
Terry Rooney, 212-223-0689
[email protected]
or
Marion Janic, 212-223-4017
[email protected]  Investors
LHA
Anne Marie Fields, 212-838-3777
[email protected]  



Read more...
Baron Opportunity Fund Comments on Illumina Guru stock highlight
Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell in the fourth quarter after reporting disappointing third quarter financial results. The third quarter shortfall was driven by weak high-throughput instrument sales. However, at the J.P. Morgan Healthcare Conference in January, Illumina announced an exciting new high-throughput sequencing platform, called NovaSeq, which has the potential in future years to deliver the world’s first $100 full human genome. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. (Neal Kaufman) Read more...
Baron Funds' Fifth Avenue Growth Fund Comments on Illumina Guru stock highlight
Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell almost 30% after reporting disappointing third quarter financial results. The shortfall was caused primarily by weak high-throughput instrument sales in North America and general weakness in Europe. Illumina’s growth is very much driven by new product introductions, and in 2016 sales suffered as the high- throughput instrument line reached the end of its life cycle. In early 2017, Illumina launched a new high- throughput sequencing platform that should re-accelerate growth. In addition, Grail, the start-up funded by Illumina which is developing a blood-based cancer screening test, announced it received capital commitments of $1 billion and would become one of Illumina’s largest customers over time. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.74
ILMN's PE Ratio is ranked lower than
67% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.08 vs. ILMN: 39.74 )
Ranked among companies with meaningful PE Ratio only.
ILMN' s PE Ratio Range Over the Past 10 Years
Min: 32.28  Med: 71.42 Max: 302.86
Current: 39.74
32.28
302.86
Forward PE Ratio 47.62
ILMN's Forward PE Ratio is ranked lower than
88% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. ILMN: 47.62 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.74
ILMN's PE Ratio without NRI is ranked lower than
67% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. ILMN: 39.74 )
Ranked among companies with meaningful PE Ratio without NRI only.
ILMN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 32.28  Med: 71.35 Max: 282.67
Current: 39.74
32.28
282.67
Price-to-Owner-Earnings 31.29
ILMN's Price-to-Owner-Earnings is ranked lower than
52% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.51 vs. ILMN: 31.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ILMN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.62  Med: 55.81 Max: 113.85
Current: 31.29
20.62
113.85
PB Ratio 10.69
ILMN's PB Ratio is ranked lower than
89% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ILMN: 10.69 )
Ranked among companies with meaningful PB Ratio only.
ILMN' s PB Ratio Range Over the Past 10 Years
Min: 2.88  Med: 7.77 Max: 23.59
Current: 10.69
2.88
23.59
PS Ratio 11.89
ILMN's PS Ratio is ranked lower than
88% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. ILMN: 11.89 )
Ranked among companies with meaningful PS Ratio only.
ILMN' s PS Ratio Range Over the Past 10 Years
Min: 3.54  Med: 9.37 Max: 17.19
Current: 11.89
3.54
17.19
Price-to-Free-Cash-Flow 71.29
ILMN's Price-to-Free-Cash-Flow is ranked lower than
89% of the 72 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.99 vs. ILMN: 71.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ILMN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.31  Med: 45.89 Max: 127.5
Current: 71.29
13.31
127.5
Price-to-Operating-Cash-Flow 41.06
ILMN's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. ILMN: 41.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ILMN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.31  Med: 33.59 Max: 344.72
Current: 41.06
10.31
344.72
EV-to-EBIT 30.04
ILMN's EV-to-EBIT is ranked lower than
61% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. ILMN: 30.04 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.9  Med: 37.7 Max: 174.6
Current: 30.04
-14.9
174.6
EV-to-EBITDA 25.96
ILMN's EV-to-EBITDA is ranked lower than
72% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. ILMN: 25.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
ILMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.6  Med: 30.5 Max: 106.4
Current: 25.96
-15.6
106.4
EV-to-Revenue 11.44
ILMN's EV-to-Revenue is ranked lower than
87% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ILMN: 11.44 )
Ranked among companies with meaningful EV-to-Revenue only.
ILMN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 9.3 Max: 17.4
Current: 11.44
2.8
17.4
PEG Ratio 1.50
ILMN's PEG Ratio is ranked higher than
71% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ILMN: 1.50 )
Ranked among companies with meaningful PEG Ratio only.
ILMN' s PEG Ratio Range Over the Past 10 Years
Min: 0.97  Med: 2.2 Max: 13.48
Current: 1.5
0.97
13.48
Shiller PE Ratio 114.76
ILMN's Shiller PE Ratio is ranked lower than
86% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.91 vs. ILMN: 114.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
ILMN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 99.64  Med: 374.34 Max: 3600
Current: 114.76
99.64
3600
Current Ratio 4.22
ILMN's Current Ratio is ranked higher than
71% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. ILMN: 4.22 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 4.09 Max: 60.21
Current: 4.22
0.99
60.21
Quick Ratio 3.73
ILMN's Quick Ratio is ranked higher than
75% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. ILMN: 3.73 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.73 Max: 60.21
Current: 3.73
0.87
60.21
Days Inventory 126.93
ILMN's Days Inventory is ranked lower than
52% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. ILMN: 126.93 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s Days Inventory Range Over the Past 10 Years
Min: 102.18  Med: 132.83 Max: 147.41
Current: 126.93
102.18
147.41
Days Sales Outstanding 53.90
ILMN's Days Sales Outstanding is ranked higher than
63% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. ILMN: 53.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.76  Med: 65.13 Max: 86.41
Current: 53.9
56.76
86.41
Days Payable 64.80
ILMN's Days Payable is ranked higher than
68% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. ILMN: 64.80 )
Ranked among companies with meaningful Days Payable only.
ILMN' s Days Payable Range Over the Past 10 Years
Min: 51.84  Med: 65.49 Max: 93.62
Current: 64.8
51.84
93.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.80
ILMN's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. ILMN: -4.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ILMN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -184.6  Med: -5.7 Max: 0.6
Current: -4.8
-184.6
0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 49.65
ILMN's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. ILMN: 49.65 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ILMN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 12.27 Max: 2050.89
Current: 49.65
1.95
2050.89
Price-to-Tangible-Book 16.07
ILMN's Price-to-Tangible-Book is ranked lower than
90% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.82 vs. ILMN: 16.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ILMN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17  Med: 8.26 Max: 461.34
Current: 16.07
1.17
461.34
Price-to-Intrinsic-Value-Projected-FCF 4.13
ILMN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
74% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. ILMN: 4.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ILMN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.53  Med: 4.5 Max: 42.17
Current: 4.13
1.53
42.17
Price-to-Median-PS-Value 1.27
ILMN's Price-to-Median-PS-Value is ranked lower than
60% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ILMN: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ILMN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.98 Max: 70.91
Current: 1.27
0.43
70.91
Price-to-Peter-Lynch-Fair-Value 1.59
ILMN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
68% of the 44 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. ILMN: 1.59 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ILMN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.37  Med: 2.6 Max: 9.54
Current: 1.59
1.37
9.54
Price-to-Graham-Number 5.33
ILMN's Price-to-Graham-Number is ranked lower than
89% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ILMN: 5.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ILMN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.51  Med: 6.37 Max: 49.18
Current: 5.33
3.51
49.18
Earnings Yield (Greenblatt) % 3.33
ILMN's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ILMN: 3.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ILMN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.5  Med: 2.4 Max: 5.9
Current: 3.33
-15.5
5.9
Forward Rate of Return (Yacktman) % 35.47
ILMN's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.48 vs. ILMN: 35.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ILMN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.7  Med: 2.6 Max: 38.1
Current: 35.47
-1.7
38.1

More Statistics

Revenue (TTM) (Mil) $2,593.37
EPS (TTM) $ 5.26
Beta0.74
Short Percentage of Float2.01%
52-Week Range $119.37 - 214.50
Shares Outstanding (Mil)146.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,698 3,038 3,355
EPS ($) 3.73 4.37 5.19
EPS without NRI ($) 3.73 4.37 5.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.66%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}